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ABSTRACT
Background and aims Alcohol use is a major contributor to injuries, mortality and the burden of disease. This
review updates knowledge on risk relations between dimensions of alcohol use and health outcomes to be used in
global and national Comparative Risk Assessments (CRAs). Methods Systematic review of reviews and meta-
analyses on alcohol consumption and health outcomes attributable to alcohol use. For dimensions of exposure: vol-
ume of alcohol use, blood alcohol concentration and patterns of drinking, in particular heavy drinking occasions were
studied. For liver cirrhosis, quality of alcohol was additionally considered. For all outcomes (mortality and/or morbid-
ity): cause of death and disease/injury categories based on International Classiﬁcation of Diseases (ICD) codes used in
global CRAs; harm to others. Results In total, 255 reviews and meta-analyses were identiﬁed. Alcohol use was
found to be linked causally to many disease and injury categories, with more than 40 ICD-10 three-digit categories
being fully attributable to alcohol. Most partially attributable disease categories showed monotonic relationships with
volume of alcohol use: the more alcohol consumed, the higher the risk of disease or death. Exceptions were ischaemic
diseases and diabetes, with curvilinear relationships, and with beneﬁcial effects of light to moderate drinking in
people without heavy irregular drinking occasions. Biological pathways suggest an impact of heavy drinking
occasions on additional diseases; however, the lack of medical epidemiological studies measuring this dimension of
alcohol use precluded an in-depth analysis. For injuries, except suicide, blood alcohol concentration was the most
important dimension of alcohol use. Alcohol use caused marked harm to others, which has not yet been researched
sufﬁciently. Conclusions Research since 2010 conﬁrms the importance of alcohol use as a risk factor for disease
and injuries; for some health outcomes, more than one dimension of use needs to be considered. Epidemiological
studies should include measurement of heavy drinking occasions in line with biological knowledge.
Keywords Alcohol use, average volume, chronic disease, injury, patterns of drinking, risk-relations, systematic
review, unrecorded consumption.
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INTRODUCTION
Alcohol consumption has been identiﬁed as a major
contributor to the burden of disease and mortality in
all the global Comparative Risk Assessments (CRAs [1])
conducted thus far as part of the Global Burden of
Disease (GBD) studies [2–7], and in the World Health
Organization (WHO) Global Status Reports on Alcohol
and Health and their predecessors [8–10]. All CRAs
restricted themselves to modiﬁable risk factors [11],
where the modiﬁcations could be linked to reductions
in the disease burden [12]. As a consequence, they have
become crucial for guiding health policy [13], not only in
terms of primary prevention [14–16], but also in terms
of secondary prevention and health systems manage-
ment [17–19].
© 2017 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction, 112, 968–1001
REVIEW doi:10.1111/add.13757
This is an open access article under the terms of the Creative CommonsAttribution-NonCommercial License, which permits use, distribution and reproduction
in any medium, provided the original work is properly cited and is not used for commercial purposes.
At the core of any CRA are the risk relations between
different dimensions of exposure (in the present case, alco-
hol use) and particular diseases, disorders or injuries. Each
of these relative risks is then combined with the extent of
the respective exposure in a particular population to create
alcohol-attributable fractions (AAFs) for that population
[20,21]. In most CRAs, including for alcohol, both the rel-
ative risk and the prevalence of exposure are continuous
functions [22]. Knowledge on and estimates of these risk
relations have been evolving during the past 15 years
(compare the overview from 2003 [23], and especially
since 2010 when the last overview on this topic in
Addiction appeared [24], which the current review will
update with the latest evidence. It will follow the structure
of the previous reviews [23,24]: ﬁrst, we will list disease
and injury categories which are 100% alcohol-
attributable; secondly, we will address disease categories
partly attributable to alcohol, and ﬁnally, injury categories
which are partly attributable to alcohol will be discussed.
In the discussion, we not only outline the limitations of
our review, but also look to future research developments.
METHODS
Search strategy
For this systematic review, we (a) searched theWHO Inter-
national Statistical Classiﬁcation of Diseases and Related
Health Problems, 10th revision (ICD-10) 2016 databank
[25] for the term ‘alcohol*’ to identify disease and injury
categories fully attributable to alcohol (see Table 1), and
(b) updated all estimates of alcohol use–disease or injury
relationships for partially attributable outcomes from the
estimates in the most recent preceding publication [24],
following the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [26,27].
We conducted a systematic literature search on AMED,
CAB Abstracts, Embase, Health and Psychosocial Instru-
ments, Healthstar, OVID Medline, PsycINFO, PubMed and
Social Work Abstracts databases to identify systematic
reviews and/or meta-analyses. Key words were different
alcohol categories and the respective outcome category,
along with either ‘systematic review’ or ‘meta-analysis’.
All databases were searched from January 2008, the time
limit of the last review of this series [24], to October
2016. Supporting information, Appendix S1 gives an over-
view on the exact search terms used and full results. To
identify the appropriate studies from the search results,
one author reviewed independently all titles and abstracts
at the initial stage. The results were compared with
previous searches and reviews conducted independently
by other authors who were part of this overview for each
health outcome category. Discrepancies between the
authors after the title and abstract review were resolved
by discussing the full text. No language or geographical
restrictions were applied. In assessing and summarizing
the results of the searches, our emphasis was on causality,
pathophysiology and the key meta-analyses.
Assessment of causality
We used the epidemiological deﬁnitions of causality, where
alcohol had to be necessary, either alone or in combination
with other antecedent conditions as a component cause
[28]. This translates into AAFs for partially attributable
outcome categories, i.e. for outcome categories for which
alcohol is a component cause. AAFs can be interpreted as
the proportion of an outcome in a speciﬁc population,
which would not occur if there had been no alcohol use
[11,29]. In discussing the various conditions, we also refer
to the Bradford Hill criteria [30], with most emphasis on
pathophysiology.
Terminology
Unless speciﬁed otherwise, we will use the term ‘heavy
drinking occasion’ for consuming quantities of 60+ g of
pure alcohol on one occasion. Chronic heavy drinking
indicates consumption on average per day of 60+ g of pure
alcohol for men and 40+ g for women (for similar thresh-
olds in alcohol exposure classiﬁcations, see [31,32]). Light
to moderate drinking is used to refer to drinking patterns
which, on average, entail fewer than 60 g of pure alcohol
per day in men and fewer than 40 g in women.
RESULTS
Disease and injury categories fully (100%) attributable to
alcohol use
In the ICD-10 [25], alcohol is mentioned as part of several
diseases and injuries, as well as in the chapter ‘Factors
inﬂuencing health status and contact with health services’
(Z codes). Table 1 gives an overview of the over 40 codes in
ICD which include ‘alcohol’ or ‘alcoholic’.
While there are more than 10000 disease and injury
codes, for only a small fraction (310) of the most frequent
and important categories are there global data on cause
of death or morbidity. All the 100% alcohol-attributable
categories in Table 1, except alcohol use disorders (F10),
are too infrequent to be included in these 310 global cause
of death or burden of disease statistical categories, either by
the Institute for Health Metrics and Evaluation (IHME)
[33] or the WHO [34]. However, GBD CRA adds estimates
for alcohol poisoning (X45) and fetal alcohol syndrome
(Q86.0) to this label. TheWHO Global Status Reports sum-
marize F10 and X45 only under alcohol use disorders. The
choice of broad categories in all global CRAs is based on the
availability and quality of data. For most of the population
world-wide, affecting 38 million of 56 million annual
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deaths globally [35], there are no vital registries with
cause of death information. For these deaths without
vital registries, cause of death is estimated on the basis
of verbal autopsies of subsamples and then scaled-up
[36]. Verbal autopsy denotes a method of gathering
health information concerning deceased individuals to
determine their cause of death. Relevant health infor-
mation and a description of symptoms and events pre-
ceding the death are determined based on interviews
with next of kin, neighbours or friends of the deceased.
This information is then analysed by trained health
professionals or computer-based algorithms to assign a
probable cause of death. The resulting cause of death
categories have to be broad, as it is impossible to deter-
mine a detailed cause of death via verbal autopsy [37].
For any non-fatal health categories, such as morbidity
or disability, the data situation is worse than for mor-
tality [38].
While almost all disease or injury categories 100%
attributable to alcohol cannot be included in the global
CRAs, they are often assessed in high-income countries
with national hospital records and vital registries and,
thus, these categories should be included in national CRAs
where possible. For example, alcoholic cardiomyopathy
(I42.6) as a cause of death is available in approximately
half of the countries as a cause of death [39], and thus
could be included as part of alcohol attributable mortality
in these countries.
Alcohol use disorders
For alcohol use disorders, as deﬁned in the F10 category of
ICD-10, causality is clear by deﬁnition, as there would not
be alcohol use disorders without alcohol use. The most
important category of alcohol use disorders in terms of
public health impact is alcohol dependence (F10.2), which
is linked both to regular and irregular heavy drinking occa-
sions (see the almost straight linear relationship between
average level of drinking and number of symptoms for
dependence [40]). The link to irregular heavy drinking
occasions ismost evident in drinking cultures such as those
in eastern Europe, where daily drinking is not common,
not even among people with alcohol dependence [41].
Alcohol dependence and other alcohol use disorders are
usually assessed based on general population surveys as
Table 1 ICD-10 categories with maximal one decimal with
mention of alcohol or alcoholic.
E24.4 Alcohol-induced pseudo-Cushing’s syndrome
F10 Mental and behavioural disorders due to use of
alcohol
F10.0 Acute intoxication
F10.1 Harmful use
F10.2 Dependence syndrome
F10.3 Withdrawal state
F10.4 Withdrawal state with delirium
F10.5 Psychotic disorder
F10.6 Amnesic syndrome
F10.7 Residual and late-onset psychotic disorder
F10.8 Other mental and behavioural disorders
F10.9 Unspeciﬁed mental and behavioural disorder
G31.2 Degeneration of nervous system due to alcohol
G62.1 Alcoholic polyneuropathy
G72.1 Alcoholic myopathy
I42.6 Alcoholic cardiomyopathy
K29.2 Alcoholic gastritis
K29.20 Alcoholic gastritis, without mention of haemorrhage
K29.21 Alcoholic gastritis, with haemorrhage
K70 Alcoholic liver disease
K70.0 Alcoholic fatty liver
K70.1 Alcoholic hepatitis
K70.2 Alcoholic ﬁbrosis and sclerosis of liver
K70.3 Alcoholic cirrhosis of liver
K70.4 Alcoholic hepatic failure
K70.9 Alcoholic liver disease, unspeciﬁed
K85.2 Alcohol-induced acute pancreatitis
K86.0 Alcohol-induced chronic pancreatitis
O35.4 Maternal care for suspected damage to foetus from
alcohol
P04.3 Foetus and newborn affected by maternal use of
alcohol
Q86.0 Fetal alcohol syndrome (dysmorphic)
R78.0 Finding of alcohol in blood
T51 Toxic effect of alcohol
T51.0 Ethanol
T51.1 Methanol
T51.2 Propanol
T51.3 Fusel oil
T51.8 Other alcohols
X45 Accidental poisoning by and exposure to alcohol
X65 Intentional self-poisoning by and exposure to alcohol
Y15 Poisoning by and exposure to alcohol, undetermined
intent
Y90 Evidence of alcohol involvement determined by blood
alcohol level—different subcategories as deﬁned by
thresholds in mg/100 ml
Y91 Evidence of alcohol involvement determined by level
of intoxication
Y91.0 Y91.0—Mild alcohol intoxication
Y91.1 Y91.1—Moderate alcohol intoxication
Y91.2 Y91.2—Severe alcohol intoxication
Y91.3 Y91.3—Very severe alcohol intoxication
Y91.9 Alcohol involvement, not otherwise speciﬁed
Z04.0 Blood-alcohol and blood-drug test
Z50.2 Alcohol rehabilitation
(Continues)
Z71.4 Alcohol abuse counselling and surveillance for alcohol
use disorder
Z72.1 Alcohol use
Z81.1 Family history of alcohol abuse
Table 1. (Continued)
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part of mental disorders (such as by the World Mental
Health Survey [42]). As such surveys are relatively infre-
quent or absent for many countries, for most CRAs to date
the prevalence of alcohol use disorders had to be estimated,
often using the level of per-capita alcohol consumption or
prevalence of heavy drinking predictors in the estimation
[43,44].
Accidental poisoning by and exposure to alcohol
Alcohol poisoning, which is the short term for the above-
speciﬁed injury category, is handled as part of alcohol use
disorders in global CRAs. Alcohol poisoning is often
assessed in hospitals for emergency room entries. Any
blood alcohol concentration above 3 g/l should be consid-
ered as potentially life-threatening, with increasingmortal-
ity risks associated with increasing blood alcohol
concentrations [45]; in many countries, cause of death
from ‘alcohol poisoning’ may be given regularly for con-
centrations above 4 g/l. However, alcohol poisonings are
underestimatedmarkedly for twomain reasons. First, alco-
hol use disorders in general are stigmatized, even over and
above the general stigma of psychiatric disorders [46]. As a
consequence, death certiﬁcates maymention more neutral
categories, such as heart disease categories, as the cause of
death ([47]; see also the discussion on alcoholic liver cir-
rhosis below). The amount of misclassiﬁcation can be sub-
stantial in some countries or regions. For example, Zaridze
and colleagues [48] reported that in a series of more than
22000 autopsies in a Russian city, 16% of decedents had
more than 4 g/l and 8% had more than 5 g/l blood alcohol
concentrations. Some of the deaths reported by Zaridze and
colleagues [48] should have been coded as alcohol poison-
ing instead of the other codes given, often cardiovascular
deaths. Similar misclassiﬁcations were found in other re-
gions of Russia and surrounding countries [49]. However,
while this means that alcohol poisoning deaths have been
under-reported, this effect is too small to explain the posi-
tive association between heavy drinking and cardiovascu-
lar mortality in countries with irregular drinking of very
large amounts of alcohol, such as the eastern European
countries [50,51]. The second reason for the underestima-
tion of alcohol poisoning are the rules applied to classify
drug overdose deaths in ICD-10 or earlier versions of the
ICD [52], which give a priority for coding other substances
than alcohol in case of involvement of multiple types of
substance use in deaths (see also [53,54]). While polydrug
use is common in drug overdose situations (e.g. [55]), and
alcohol is one of the substances often present with other
illicit substances, alcohol is rarely recorded as the cause
of death, even when it has been speciﬁed and reported as
the most toxic component by the medico-legal pathologist,
and based on this should have been coded as the underly-
ing cause of death [56].
Fetal alcohol spectrum disorders
Fetal alcohol spectrum disorders (FASD) are the leading
known cause of preventable birth defects and develop-
mental disabilities. FASD is an umbrella term that
describes the full spectrum of deﬁcits that can occur in
prenatally alcohol-exposed individuals. The most severe
and important form of FASD in terms of public health,
fetal alcohol syndrome (FAS), is characterized by clear
morphological changes, functional deﬁcits and high prev-
alence of comorbidities [57]. FAS is the only expression of
FASD in the ICD-10 (see Table 1). While FASD is not yet
in ICD, the 5th edition of the Diagnostic and Statistical
Manual of Mental Disorders included ‘Neurobehavioral
disorder associated with prenatal alcohol exposure’ under
‘conditions for further study’ as the ﬁrst step before
including it as a formal diagnosis for clinical use (see
Supporting information, Appendix, Section III [58]).
Studies by May and co-workers [59–61] give some indi-
cation of the full spectrum of FASD.
While human research has not delineated, and per-
haps cannot delineate fully, the pattern, amount and/or
critical period of alcohol exposure necessary for struc-
tural and/or functional teratogenesis, animal models
have shown that all stages of embryonic development
are vulnerable to the teratogenic effects of ethanol, and
that the type and severity of ethanol-induced birth
defects are dependent largely upon the pattern, dose
and developmental stage of the embryo at the time of
ethanol exposure [62,63]. Animal models demonstrate
clearly that even low levels of prenatal alcohol exposure
may lead to brain dysfunction which, in turn, contributes
to behavioural abnormalities [64].
In human research, the link between heavy drinking
occasions during pregnancy and the risk of FAS is well
established [65–70]. For low amounts of alcohol
(8–28 g per occasion), several studies have found that
there is no increased risk of behavioural and/or develop-
mental deﬁcits in children [69,71–73]. However, there is
some evidence that the consumption of 42–56 g per
week during pregnancy may have adverse effects on
neurodevelopment [70]. To date, however, there are no
longitudinal human studies that have followed alcohol-
exposed individuals over a sufﬁcient amount of time
and used FASD diagnostic criteria to establish the rela-
tionship between dose and/or pattern of alcohol intake
during pregnancy and FASD.
For estimation of the prevalence of FAS and FASD,
Popova and colleagues developed a methodology based
on the prevalence of drinking during pregnancy, which
will be used in future CRAs [74]. However, disability
weights [75] need to be established for both categories
to estimate the burden of disease (currently only avail-
able for FAS [76]).
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Disease and injury categories partially attributable to
alcohol use
In total, 255 unique reviews andmeta-analyses were iden-
tiﬁed (see Supporting information, Appendix S1). Table 2
gives an overview of global cause of death and outcome
categories causally impacted by alcohol, as well as themost
important meta-analyses, including those used for the
CRA of the upcoming WHO Global Status Report on
Alcohol and Health (to be prepared in 2017; for graphs
on the relationships between average level of alcohol use
and disease, see Supporting information, Appendix S2).
In the following sections, we discuss the underlying
reasons and pathways for major disease, injury and
cause of death categories where causality has been
established. An important consideration for each disease
and mortality outcome are the questions of (a) which
dimension of alcohol use is causally related; (b) if there
are dose–response relationships within the respective
dimension; and (c) whether there are gender differences
(see also Supporting information, Appendix S2 for gender
speciﬁc formulas). The overall results on modelled and
biological relationships are summarized in Table 3.
Infectious diseases
Alcohol’s effects on the immune system
Alcohol impacts the innate and the acquired immune
system and, thus, increases vulnerability to infectious
disease [77,78]. Alcohol exposure impairs the functioning
of phagocytes such as polymorphonuclear leucocytes
(especially neutrophils) and macrophages [79]. These cells
are responsible for the ingestion of dead cells and can be
considered the immune system’s ﬁrst responders to inﬂam-
mation [80]. Alcohol exposure has a suppressive effect on
the release of cytokines responsible for cell signalling and
critical for regulation of the host defence [80,81]. This
includes chemotactic signals that trigger the migration of
polymorphonuclear leucocytes into the infected area. The
effects of chronic alcohol use on the immune response
are probably also to increase the risk of infectious disease
[82,83]. Overall, the biological pathways suggest a more
pronounced effect of heavy drinking occasions and, thus,
more exponential pathways and a speciﬁcally high risk
for alcohol use disorders.
Tuberculosis
Alcohol’s impact on the immune system described above is
immediately relevant to infectionwith tuberculosis (TB), as
approximately one-third of people in the world have been
infected with Mycobacterium tuberculosis but are not yet ill
and cannot transmit the disease (latent TB [84]). However,
only 10% of those infected develop active TB; for the rest,
the immune system will be able to ﬁght off the infection.
Accordingly, a weakened immune system is critical for
increasing susceptibility to TB infection, or for reactivation
of latent TB, and alcohol plays a prominent role here [85].
As a second important pathway, alcohol use may lead to a
presence in social environments that facilitate the spread of
tuberculosis infection [85]. As a consequence, alcohol is
one of the major risk factors for TB, especially in countries
with high population densities and high infection rates of
M. tuberculosis, with poverty being linked to both. Regard-
ing for average level of consumption, there is clearly a
dose–response relationship, with some indication that, for
lower levels of consumption, the increase is less steep than
for higher levels [86,87].
Given the aetiology, one may suspect an impact of
patterns of drinking, especially of irregular heavy drink-
ing occasions, but the empirical evidence is scarce [88].
In addition, the higher relative risks for alcohol use disor-
ders or alcohol problems may serve as an indirect indica-
tor [86,87], as both are usually linked to heavy drinking
occasions [40,89,90].
HIV/AIDS
The status of alcohol use as a cause for HIV infection,
separate from its general impact on the immune system
(see above), and of the effects of alcohol use on the
course of HIV/AIDS, separate from non-adherence to
anti-retroviral medications [91,92], have been discussed
in recent years [93–96]. Indeed, the evidence on both
mechanisms was found to be non-conclusive in most
publications, and also at a meeting to discuss the
causal role of alcohol use in HIV/AIDS organized by
the WHO and the South African Medical Research
Council in 2008 [97]. However, since 2008, consider-
able new scientiﬁc evidence has emerged which sup-
ports a causal role of alcohol. Systematic reviews and
meta-analyses are now available to allow the quantiﬁ-
cation of the impact of alcohol use on HIV/AIDS. In
the following, we try to summarize recent developments
(following closely [98]; see also [99]), and suggest an
operationalization to quantify the causal impact of
alcohol use on HIV/AIDS.
Alcohol use was found to be associated with HIV inci-
dence and prevalence in systematic reviews and meta-
analyses [100–106]. This association may have resulted,
in part, from the causal impact of acute alcohol use on
sexual decision-making [107], resulting in condomless
sex [105,108–114]. Alternatively, other variables could
be causally responsible for the associations between alco-
hol use and HIV/AIDS, especially the effect of risk-taking
behaviours and other personality traits [96,115].
To exclude such alternative explanations and corrobo-
rate the causal role of alcohol on HIV incidence via impacts
on decision-making concerning safer sex practices, a
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number of experiments have been conducted. Alcohol use
was manipulated experimentally to assess its impact on
condomless sex intentions. Systematic reviews and
meta-analyses of the results of these experimental trials
clearly indicated the causal impact of acute alcohol use
(clearly shown for a blood alcohol concentration of
0.07 g/dl or more, but possibly even below) use on
decisions/intentions about condomless sex, above and
beyond the inﬂuence of expectations about alcohol and of
underlying risk-relevant personality traits [113,114]. It
should be noted that these experiments have been
conducted in a number of key populations, including
HIV-positive people [116].
Clearly, any experimental studies on alcohol use and
HIV can only use surrogate end-points, i.e. intention for
unsafe (condomless) sex rather than condomless sex itself
or HIV infection. However, the results of the experimental
studies corroborate the results of epidemiological cohort
Table 3 Biological pathway and Comparative Risk Assessment (CRA) modelling of alcohol use and health outcomes.
Statistical model Biological pathway
Disease category General regression of alcohol use on logarithmized RR
Irregular
HD HD
Irregular
HD
Infectious diseases
Tuberculosis Linear  + +
Human immunodeﬁciency virus/
acquired immune deﬁciency syndrome
(HIV/AIDS)
Modelled indirectly via sexual decision making and
impact on medication adherence
+ + +
Other sexually transmitted diseases Modelled indirectly via sexual decision-making + + +
Lower respiratory infections:
pneumonia
linear  + ?
Cancers
Lip and oral cavity cancer Almost linear   
Nasopharynx cancer Almost linear   
Other pharynx cancer Almost linear   
Oesophagus cancer Almost linear   
Colon and rectum cancer Almost linear   
Liver cancer Accelerated   
Larynx cancer Almost linear   
Female breast cancer Slightly accelerated  Some indications 
Diabetes mellitus
Diabetes mellitus Curvilinear + + ?
Neuropsychiatric disorders
Alzheimer’s disease and other
dementias
Not clear; indications for curvilinear  + 
Unipolar depressive disorders Threshold  + ?
Epilepsy Linear  + ?
Cardiovascular diseases
Hypertensive heart disease Accelerated  + ?
Ischaemic heart disease Curvilinear + + +
Cardiomyopathy Modelled indirectly via the proportion of alcoholic
cardiomyopathy to cardiomyopathy in the countries
with data
+ + +
Atrial ﬁbrillation and ﬂutter Linear  + +
Ischaemic stroke Curvilinear + + +
Haemorrhagic and other non-
ischaemic stroke
Linear for women; accelerated for men  + +
Gastrointestinal diseases
Cirrhosis of the liver Accelerated  + 
Pancreatitis Curvilinear for women; linear for men  + +
Injuries
Unintentional injuries Modelled mainly via drinking level in the situation + + (tolerance) +
Violence Modelled mainly via drinking level in the situation + ? +
Suicide Modelled based on both volume of drinking and
drinking in the situation
+ + +
RR: relative risk; HD: chronic heavy drinking; irregular HD: irregular heavy drinking.
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and cross-sectional studies with condomless sex
[105,108–112,117–120], sexually transmitted diseases
[121,122] or HIV incidence [102] as end-points.
Moreover, there are meta-analyses that show a clear link
between intentions for condomless sex and actual sexual
risk behaviour [123,124], as well as between condomless
sexual practices and HIV seroconversion [125–127].
Besides this pathway of sexual decision-making, there
are ﬁndings of biological effects of alcohol use on HIV trans-
mission and disease progression ([128] gives an overview;
see also [129–131]). These include clear evidence that
heavy drinking or alcohol use disorders are associated with
viral load increases and/or CD4 count declines, mediated
partly by treatment adherence and partly by the pharmaco-
logical interactions with anti-retroviral and other medica-
tions to treat comorbidities (for mechanisms see
[99,128,130,132–134]; for pharmacological interactions
see [135,136]). It should be noted, however, that delineation
and quantiﬁcation of causality in these biological pathways
is difﬁcult, as many factors interact [128,134,136,137].
The above considerations allow only a conservative
operationalization of the causal impact of alcohol use on
HIV/AIDS based on its causal effect on decision making,
assuming that there is a threshold for alcohol’s effect on
decision-making of four drinks for women and ﬁve drinks
for men (approximately 48+/60+ g on one occasion). A
further causal impact is the effect of alcohol on impeding
adherence to anti-retroviral medications [92]. The estima-
tion of relative risk based on these two mechanisms is
conservative in its assumptions, and the resulting AAFs
are markedly lower than those from modelling exposure
with relative risk for incidence [102] using the usual
methodology for CRAs (see [98] for a comparison; for
usual modelling strategies see [11]).
Sexually transmitted diseases excluding HIV
Other sexually transmitted diseases have been found to be
associated with alcohol use, especially with heavy drinking
occasions [121]. While some speciﬁc biological pathways
may vary, the general impact of alcohol use on the immune
system (see above) is also relevant for the incidence of these
diseases. Moreover, the behavioural causal pathway of
alcohol’s impact on decision-making should be the same
[98,99], so we suggest the same AAFs as for HIV/AIDS
(excluding the AAF for the effect of alcohol use on
mortality due to medication non-adherence). The latter
effect was speciﬁc for HIV/AIDS, as missing anti-retroviral
medications was shown to have marked effects on mortal-
ity [92], an effect not applying to medications for other
sexually transmitted diseases. Moreover, the interactions
between medications for HIV/AIDS and alcohol are not
observed for medications for other sexually transmitted
diseases and alcohol.
Lower respiratory infections: pneumonia
The constant exchange with the environment presents a
speciﬁc challenge to the immune defences of the lower
respiratory tract. Apart from the general immunosup-
pressive effects explained above, chronic alcohol exposure
speciﬁcally impairs the immune defences and functioning
of the lower respiratory tract, increasing the risk of both
viral and bacterial pneumonia. Chronic alcohol exposure
decreases saliva output, which leads to an increased col-
onization of bacteria in the oropharynx [138]. Ciliary
movement that is responsible for the transportation of
trapped airborne particles and microorganisms can be
impaired by heavy alcohol use, and the normal cough
reﬂex can be weakened, increasing the risk of aspiration
of oropharyngeal bacteria [80]. Finally, chronic alcohol
use severely impairs alveolar macrophages that consti-
tute the ﬁrst line of the cellular immune defence of the
lungs [79,138,139]. For an overview of the physiological
mechanisms, see [138] and [140].
While the effect of alcohol use on pneumonia has been
recognized since the 18th century [141], there has been a
scarcity of systematic reviews and meta-analyses quantify-
ing the relative risk associated with different levels of alco-
hol use. The work of Samokhvalov and colleagues still
seems to be the best review and quantitative summary
[142]. In line with what would be expected, based on the
physiological effects, heavy and prolonged alcohol use
and alcohol use disorders have been linked speciﬁcally to
a high risk, while evidence of the effects of lower levels of
use is less clear.
Cancers
The carcinogenic effects of ethanol (the main carcinogenic
compound in alcoholic beverages [143]) and its
metabolites have been acknowledged by the International
Agency for Research on Cancer (IARC) in three mono-
graphs [144–146], as well as by the Continuous Update
Project of the World Cancer Research Fund and the Amer-
ican Institute for Cancer Research [147]. Speciﬁcally, the
biological, animal and epidemiological evidence has re-
sulted in alcohol being classiﬁed as a group 1 carcinogenic
agent for humans (i.e. the highest level of evidence of car-
cinogenicity; for guidelines and evaluation criteria see
[148]). Furthermore, the most recent IARC monographs
found sufﬁcient animal and epidemiological evidence to
conclude that alcohol consumption plays a causal role in
oral cavity, pharyngeal, laryngeal, oesophageal (limited to
squamous cell carcinoma (SCC), liver, colon, rectal and
female breast cancers [149], as well as some evidence for
a probable relationship between alcohol consumption and
stomach and pancreatic cancers [146]. Lastly, there is
limited epidemiological evidence of a relationship between
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alcohol consumption and kidney, thyroid, prostate, ovarian
and endometrial cancers and Hodgkin’s and non-
Hodgkin’s lymphoma [149]. Thus, the causal role of
alcohol in the development of these cancers is uncertain.
There are various biological pathways by which the use
of alcohol increases (and possibly decreases) the risk of can-
cer; the exact pathways are often unknown and likely to
vary by cancer site. Based on current evidence, the main
pathway by which alcohol use is hypothesized to increase
the risk of cancer is through themetabolism of ethanol into
its carcinogenic metabolite acetaldehyde, which forms
DNA adducts leading to the development of cancer (see
review in [143]). There are at least four other pathways
by which alcohol use may increase the risk of cancer. First,
alcohol may alter the one carbon metabolism by inhibiting
folate absorption, leading to increased homocysteine
concentrations [150,151], and by inhibiting folate cycle
enzyme methionine synthase and the trans-methylation
enzymes methionine adenosyltransferase and DNA meth-
yltransferase [150,152]. Secondly, alcohol may affect
serum levels of hormones and related signalling pathways,
leading to an increased risk of breast cancer, and possibly of
prostate, ovarian and endometrial cancers [153–155].
Thirdly, alcohol consumption may lead to alterations in
serum levels of insulin-like growth factor (IGF); however,
this relationship is complex, withmoderate chronic alcohol
consumption increasing serum levels of IGF, and acute
alcohol consumption leading to a decrease in IGF levels
[156]. Lastly, alcohol also has a strong interaction with
tobacco smoking, particularly in terms of its carcinogenic
effects on the oral cavity and oesophagus (SCC).
Speciﬁcally, alcohol acts as a solvent for tobacco
carcinogens [157,158].
Conversely, alcohol may prevent the development of
cancer through two biological pathways. First, by increas-
ing insulin sensitivity, alcohol may decrease the risk of
kidney cancer [159,160]; in contrast, insulin resistance
has been observed to be a risk factor for cancer indepen-
dent of other risk factors such as obesity [161,162].
Furthermore, the World Cancer Research Fund has found
that there is strong evidence to suggest that alcohol con-
sumption below 30 g per day on average is related causally
to a decrease in the risk of developing kidney cancer [163].
Secondly, resveratrol (the ‘red wine chemical’) has gained
attention for its protective effects on the development of
cancer [164–166] through its ability to inhibit nuclear fac-
tor kappa B (NF-κB) (thus creating an anti-inﬂammatory
effect) and activator protein-1 (AP-1) transcription (thus
inhibiting the conversion of procarcinogens into carcino-
gens [167]). However, the effect of resveratrol in decreasing
the risk of cancer is minimal, at best. To exhibit a protective
effect against cancer (i.e. reduce the incidence of certain
cancers of colon, liver and female breast) a certain mini-
mum daily dose of resveratrol is required, and below this
dose there will be no possible protective effect. The amount
of resveratrol in wine is approximately a factor of 100000
or more below this minimal effective daily dose and, thus,
no protective effect is to be expected from such a low
dosage (this would be similar to ingesting 1/100000 of
an aspirin tablet [168]).
The increase in the risk of developing cancer (stratiﬁed
by cancer site) for increasing average daily amounts of
alcohol consumed (measured in grams of pure alcohol
consumed per day) has been observed to be linear on an
exponentiated scale; however, the magnitude of these risk
increases varies by cancer site [169–171]. Furthermore,
as with other diseases related causally to alcohol consump-
tion, the relative risks for cancer are dependent upon the
systematic search strategy, inclusion and exclusion criteria,
reference group (and if this includes former drinkers) of the
underlying studies [172–174], use of case–control and/or
cohort studies [175] and use of categorical or continuous
estimates for alcohol consumption [169] (for relative risk
graphs see [176] and Supporting information, Appendix S2).
No threshold for the effects of alcohol use on the risk of
cancer has been detected; however, especially for breast
cancer, there is ample evidence of alcohol’s effects even at
low levels of average consumption [177–179]. This results
in a large breast cancer burden from relatively low doses
(< 21 g per day) of alcohol [179]. Furthermore, there is
currently not enough epidemiological evidence to assess if
the pattern of alcohol consumption modiﬁes the risk of
breast cancer [151]. The main biological pathway seems
to be through overall tissue exposure to acetaldehyde,
which may not be affected by drinking patterns; however,
through modiﬁcations of insulin-like growth factor (IGF)
serum levels, drinking patterns may have an effect on the
risk of developing breast cancer (as well as other cancers,
where modiﬁcations to IGF serum levels play a role [180]).
The risk relationship between alcohol consumption and
the development of cancer has been shown to be modiﬁed
by genetic variations in the carbon metabolism pathway
and the ethanol–acetaldehyde metabolic pathways
[181,182]. Speciﬁcally, genetic variations in the aldehyde
dehydrogenase 2 gene have been shown to affect the risk
relationship between alcohol consumption and oral cavity
and oesophageal cancer [175,181,183]. As the prevalence
of these genetic variations differs in different national
populations, cancer is the ﬁrst alcohol-attributable disease
category where genetic considerations play a role in
modelling the effect of alcohol use in global CRAs of the
GBD and the WHO (for a ﬁrst such attempt, see [184]).
Overall, the alcohol-attributable cancer disease and
mortality burden is high [8,178]. However, current esti-
mates of the number of cancer cases and cancer deaths
caused by alcohol are limited due to the inability to incor-
porate biological latency which, for many cancer sites,
can be 20 years or more [185,186]. Future CRA studies
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will need to take into account this latency and the compet-
ing risks from alcohol-related and -unrelated deaths [187].
Diabetes mellitus
There seems to be a beneﬁcial effect of alcohol use on
diabetes mellitus type 2 incidence [188], as evidenced in
meta-analyses and in systematic reviews [189–193]. How-
ever, this seemingly unambiguous picturemust be qualiﬁed
by different results by gender and ethnicity. For instance,
stratiﬁcation of available data in the latest and most com-
prehensive meta-analyses by Knott and colleagues [192]
revealed that reductions in risk may apply to women only
and may be absent in studies sampled in the Asian region.
In addition, Knott [192] found that some beneﬁcial effects
disappeared when compared to life-time abstainers, a prob-
lem not unique to diabetes ([174]; see belowand discussion
in [173]). Also, intervention studies about the effects of
reductions in the consumption of alcohol on glucose and
insulin biomarkers in people with and without diabetes
showed mixed results [194,195]. Irregular heavy drinking
occasions may play a role in explaining the differences
between studies and in the reviews (e.g. [196,197]), but
there are not enough epidemiological studies on diabetes
including this dimension of alcohol exposure to settle this
question.
Whether a beneﬁcial effect of alcohol on diabetes
should be modelled in future CRAs will be a discussion in
the respective technical advisory committees. This decision
has important public health relevance (see [198] for addi-
tional considerations), as the effect is fairly large, given
the prevalence of diabetes mellitus world-wide [199,200]
and the relatively high effect size found in epidemiological
studies on alcohol use and the incidence of type 2 diabetes
mellitus [191,192].
Neuropsychiatric disorders
Alzheimer’s disease, other dementias and cognitive decline
The relationships of alcohol use to Alzheimer’s disease,
other forms of dementia and cognitive decline seem to be
complex. On one hand, there is a possible protective effect
of light to moderate drinking [201–203]. On the other
hand, systemic reviews revealed inconsistent results about
a potential protective effect of alcohol use [204,205]. Sev-
eral subtypes of dementia are clearly related detrimentally
and causally to heavy drinking [206], and the most com-
prehensive review exhibited a J- or U-shaped relationship
between the intensity of alcohol use and the direction of
the effect [207]. A recent review also found evidence that
heavy alcohol use predicts conversion from any type of
mild cognitive impairment to dementia, and inconsistent
evidence about whether moderate alcohol use predicts risk
of dementia [208]. In addition, a Mendelian randomization
study did not provide any evidence of a causal impact of
alcohol use on cognitive performance, although admittedly
this is a more general concept than the disease categories
discussed above [209].
Overall, while the negative impact of heavy drinking on
dementia and cognitive functioning seems indisputable,
with identiﬁed biological pathways [210,211], a protective
effect of light to moderate drinking has some biological
plausibility [212], but evidence on this is inconsistent. This
is due partly to the multitude of methodological problems
which every review describes (e.g. see discussion in
[213]), such as inconsistent measurement of exposure
and outcomes, inconsistent control of potential con-
founders and lack of consideration of sample attrition due
to mortality.
Major depressive disorders
Most mental disorders, including major depressive disor-
ders, have consistent associations with alcohol use, and
especially with heavy drinking and alcohol use disorders
[79–81,214–217]. In addition to these associations, both
the Diagnostic and Statistical Manual of Mental Disorders,
5th edition [58] and the ICD-10 ([25]; see also [218]) list
alcohol-induced mental disorders, including alcohol-
induced depressive disorders, thus building causality into
the disorder category. However, these codes are not used
in most countries (an exception is the United States, where
it is a billable code for medical services), so we need to
establish estimates of the causal impact of alcohol use on
major depressive episodes in other ways.
There are three possible descriptions of the potential
causal pathways that underlie the association between
heavy alcohol use and alcohol use disorders and major de-
pressive disorders [5,219]: (a) heavy drinking/alcohol use
disorders cause depressive disorders; (b) depressive disor-
ders increase alcohol use and cause alcohol use disorders
(often discussed under the heading of a ‘self-medication’
hypothesis [220]); and (c) a reciprocal causal relationship
or causation by another mechanism such as genetic
vulnerability. Two reviews on this topic came to the same
conclusion: that all three mechanisms are possible and
probably existing, but the ﬁrst mechanism—that alcohol
use (especially heavy use and alcohol use disorders) causes
depression—is stronger andmore prevalent than the other
pathways ([5,219]; see also [221,222]).
How to estimate the causal impact of alcohol use on
major depressive disorders remains in question. Given the
current scarcity of meta-analyses on alcohol use as a risk
factor for major depressive disorders, this probably has to
be performed indirectly from the risk relationships of
alcohol use disorders and depressive disorders [219].
To be conservative, these risk relationships should be
applied only to depressive disorders with later onset
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than alcohol use disorders. Alternatively, the
confounder-controlled risks from Fergusson and
colleagues [221] could be used [odds ratio (OR) = 1.66,
95% conﬁdence interval (CI) = 1.08–2.55]. Both
suggested solutions are conservative, as it has been
demonstrated that alcohol use levels below heavy
drinking are associated with higher risks than absten-
tion [223].
In addition to its role in the aetiology of depressive
disorders, alcohol use has been associated with worsen-
ing the depression course, and worse outcomes such as
suicide/death risk, social functioning and health care
utilization ([214]; speciﬁcally for suicide, see section
on injury below). However, the literature on this is
not detailed enough to derive reliable quantitative risk
relationships.
Unprovoked seizures and epilepsy
The association between alcohol use and seizures has been
known since ancient times, with alcohol withdrawal
seizures being the best studied and described aspect
[224,225]. However, in terms of public health, the effect
of alcohol use on the development of epilepsy and seizures
not resulting directly from alcohol withdrawal is more im-
portant ([224–228]; for an exact deﬁnition see [229]). A
meta-analysis of the data on unprovoked seizures from six
available studies showed an overall association between
alcohol use and the risk of epilepsy with a pooled relative
risk (RR) of 2.19 (95% CI = 1.83–2.63). In addition, there
was a dose–response relationship, with RRs of 1.81 (95%
CI = 1.59–2.07), 2.04 (95% CI = 2.00–2.97) and 3.27
(95% CI 2.52–4.26) for consuming 48, 72 and 96 g pure
alcohol per day, respectively [224,230]. Alcohol use also
fulﬁlled other Bradford Hill criteria, such as temporality
and biological plausibility [225,228]. The time for develop-
ing epilepsy or repetitive unprovoked seizures in heavy
drinkers is 10 or more years [228]. The most plausible bio-
logical pathway is described by the ‘kindling effect’, which
postulates that repeated withdrawals, even subclinical,
may lead to gradual lowering of the seizure threshold and
eventually to the development of epilepsy, or unprovoked
seizures that occur even in those who no longer consume
alcohol [231,232]. Other theories postulate cerebral
atrophy, cerebrovascular infarctions, lesions, traumas,
neuroplasticity and chronic electrolyte imbalances as lead-
ing to the onset of seizures [233–235]. In addition, alcohol
use may affect the clinical course of pre-existing epilepsy ei-
ther by changes in anti-epileptic drug pharmacokinetics or
by non-compliance with prescribed medication [236,237].
Cardiovascular diseases
The relationship between alcohol use and cardiovascular
disease outcomes is complex, as different dimensions
play a role for different outcomes [238–240]. Clearly,
chronic heavy drinking is detrimental (for blood
pressure/hypertension [241,242]; ischaemic heart disease
[243]; cardiomyopathy [244]; atrial ﬁbrillation and ﬂutter
[245]; all types of stroke [246]), but there is also evidence
for an increased risk associated with irregular heavy drink-
ing, even in people who are on average light to moderate
drinkers (ischaemic heart disease [247–249]; ischaemic
stroke [250]; all types of stroke [251]; different cardiovas-
cular outcomes [252]). For the effects of irregular heavy
drinking occasions on cardiovascular disease, there are
potentially four main mechanisms [253]. First, irregular
heavy drinking increases the risk of coronary artery disease
via unfavourable impacts on blood lipids. Secondly, there
are effects on clotting, increasing the risk of thrombosis.
Thirdly, irregular heavy drinking affects the conducting
system, leading to a greater risk of arrhythmias [254].
Finally, any heavy drinking increases blood pressure,
leading to acute or sustained hypertension [255].
With respect to non-heavy drinking, there are beneﬁ-
cial and detrimental effects. Beneﬁcial effects are seen
mainly for ischaemic diseases, i.e. ischaemic heart disease
and ischaemic stroke [256,257]. While these beneﬁcial
effects have been put into question for different reasons
(e.g. [174,258,259]), and while they may be
overestimated using standard epidemiological methodol-
ogy because of biased comparison groups [260], biological
pathways corroborate some protective effect. The basic
biological pathways for beneﬁcial effects on ischaemic
diseases are favourable changes in several surrogate
biomarkers for cardiovascular risk, such as higher levels
of high density lipoprotein cholesterol and adiponectin
and lower levels of ﬁbrinogen [255,261,262]. However,
the situation may be more complex, as there are
indications that the beneﬁcial effect on ischaemic out-
comes cannot be found in certain countries such as India
[263,264]. It remains to be seen if this reﬂects different
drinking patterns among those who are, on average, light
to moderate drinkers, or if there are genetic inﬂuences on
the biological pathways leading to cardioprotection of light
to moderate alcohol use (see also [249]).
As different dimensions of alcohol use impact upon car-
diovascular outcomes, instrumental variable approaches
such as Mendelian randomization cannot answer ques-
tions of causality easily, as they assume linear relations
with one dimension (for Mendelian randomizations studies
see [259,265]; for a discussion of different dimensions of
alcohol use with divergent predictions see [266]).As a
result, modelling of alcohol use on cardiovascular disease
outcomes also has to take different dimensions of exposure
into account. In the most recent CRAs, this was solved as
follows [22,267]:
• For hypertensive heart disease, ischaemic heart dis-
ease and both stroke types, the risk relations are
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speciﬁed for fatal and non-fatal outcomes. Moreover,
for ischaemic diseases, we used age-speciﬁc risk rela-
tions [268].
• For countries in eastern Europe (Russia and surrounding
countries with similar drinking patterns), different rela-
tive risk estimates were used ([269], based on [270]).
In particular, no beneﬁcial effect was modelled because
of detrimental drinking patterns and higher relative risk
per heavy drinking occasion, as the average quantity per
heavy drinking occasion in these countries is higher (see
[41,271–273] as background).
• For all countries, for ischaemic heart disease and ischae-
mic stroke, we used risk relations which changed the risk
function below 60 g of pure alcohol per day based on the
presence or absence of heavy drinking occasions [268].
Modelling the impact of alcohol use this way for all
countries in the WHO European Region between 1990
and 2014 revealed that alcohol-attributable cardiovascu-
lar mortality was key to understanding the trends in
alcohol-attributable mortality as a whole [178,274]. For
most countries in the region, alcohol-attributable cardio-
vascular mortality was close to zero, as the detrimental
effects on hypertensive heart disease, atrial ﬁbrillation
and haemorrhagic stroke more or less balanced the beneﬁ-
cial effects on ischaemic heart disease and ischaemic stroke
[178]. However, for countries with more heavy drinking
occasions in the eastern part of the region, there was con-
siderable alcohol-attributable cardiovascular mortality; in
some countries such as Russia, this even constituted the
highest category of alcohol-attributable mortality ([178];
see also [275]).
Gastrointestinal diseases
Liver cirrhosis
Liver cirrhosis and the wider GBD category with other liver
diseases is a major cause of death globally [200], even
though it has not been included into the WHO targets for
non-communicable disease [276]. Liver disease is linked
clearly to alcohol [277], evidenced by several ICD codes
for alcoholic liver diseases (Table 1), including simple
alcoholic steatosis, hepatitis, ﬁbrosis and cirrhosis and
superimposed hepatocellular carcinoma, which is part of
alcohol-attributable cancers (see above). Globally, approxi-
mately half of all liver cirrhosis deaths and disability-
adjusted life years were estimated to be attributable to
alcohol in 2012 [8].
The pathogenesis of speciﬁc forms of alcoholic liver dis-
ease can be summarized as follows [278,279]. Alcohol use,
especially heavy drinking occasions, induces changes in
lipid metabolism (increases lipogenesis and mobilization of
lipids and simultaneously decreases hepatic lipid catabo-
lism), resulting in the accumulation of lipids in hepatocytes
called fatty liver. Alcohol use can also cause an inﬂamma-
tory response known as alcoholic hepatitis, or
steatohepatitis if it is accompanied by hepatic lipid deposi-
tion. Although hepatic steatosis does not normally cause
irreversible hepatic changes, persistence and severity of
alcoholic hepatitis or steatohepatitis leads eventually to
ﬁbrosis and sclerotic changes in the liver that result in
insidious replacement of hepatocytes with connective
tissue (liver cirrhosis) and subsequent liver failure.
The dose–response relationship between average vol-
ume of alcohol use and liver cirrhosis is exponential, with
the curve more pronounced for mortality than for non-
fatal morbidity [280]. The more accelerated dose–response
curve for mortality is due to the fact that liver damage can
have different aetiologies (most prominently, hepatitis B or
C [281]), but if the liver is damaged continuation of alcohol
use, even at relatively low quantities, can lead to death.
Most research about the relationship between alcohol use
and liver disease examined the overall tissue exposure
(i.e. overall volume of alcohol consumption) following the
tradition of Lelbach [282]. However, there are also indica-
tions that patterns of drinking matter [283]. More speciﬁ-
cally, given the same amount of overall alcohol exposure,
days without any alcohol consumption (‘liver holidays’)
have been shown to be associated with a lower risk than
daily drinking [284,285].
Another dimension of alcohol use has been discussed
speciﬁcally for liver cirrhosis: the quality of the alcoholic
beverage, and particularly potential problems with hepato-
toxic ingredients in unrecorded consumption (e.g. [286].
Unrecorded consumption denotes all alcohol that is not
registered and thus not controlled by routine state activi-
ties, such as home-made, illegally produced or smuggled
alcohol (for a deﬁnition see [287]). While there have been
some instances where ingredients of unrecorded alcohol
have been found which could cause liver problems over
and above the impact of ethanol [288,289] these instances
are limited, and the overall conclusion of relevant reviews
has been that there is not sufﬁcient evidence to link a
sizable portion of liver cirrhosis mortality to unrecorded
alcohol ([290,291]; see also [292]).
Another issue is the fact that alcoholic liver disease can-
notbemeasured reliablyviausual deathregistries or viaver-
bal autopsies, as the assessment of whether a liver disease is
due to alcohol use or other risk factors is impacted highly by
socio-cultural factors, in particular by stigma [46]. In their
seminal study in 12 cities in 10 countries, Puffer & Grifﬁth
[293] found that after triangulating data on death certiﬁ-
cates with data from hospital records and interviews of
attending physicians or family members, the number of
deaths with alcoholic liver cirrhosis more than doubled,
with themajorityofnewcasesbeing recoded fromcategories
of cirrhosis which do not mention alcohol. This under-
reporting of alcoholic liver cirrhosis has persisted in later
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studies [294–296]; this seems to be the case for all disease
categories fullyattributable toalcoholuse [296,297] includ-
ing,butnot limited to, thedisclosureofalcoholusedisorders.
As a consequence, in national CRAs based on death
registries, estimations of alcohol-attributable liver diseases
should not be based on routine data from these registries,
but estimated indirectly viameasureswhich have no or less
bias (such as attributable fractions of liver cirrhosis or liver
disease in general). Exceptions should be made only for
countries where there had been empirical studies on the
validity of alcoholic liver disease as a cause of death.
Pancreatitis
As is the case for liver diseases (see above), there are ICD-10
codes for alcoholic pancreatitis (see Table 1). The patho-
genesis is different for acute and chronic pancreatitis, but
alcohol use has a signiﬁcant impact on the pathophysiol-
ogy of both [298–302] and in the transition from acute
to chronic pancreatitis (see [303]). Speciﬁcally, in chronic
pancreatitis, metabolism of alcohol leads to production of
reactive oxygen species [304] and fatty acid ethyl esters
[305,306] that activate stellate cells and damage acinar
cells of the pancreas. This process is mediated by sustained
elevation of the cytosolic Ca2+ levels [307] and results
ultimately in releasing pancreatic enzymes into the
interstitium and in chronic inﬂammation [299]. In acute
pancreatitis a similar cascade of intra- and extracellular
reactions leads to fatty acid ethyl esters (FAEE)-induced
increase of the Ca2+ release which results in massive
necrosis of pancreatic acinar cells [307] and acute
inﬂammation.
Regarding epidemiological results, the dose–response
relationship seems to be accelerated for higher doses
[308,309], more pronounced in women, and in acute
pancreatitis. There were not enough data to evaluate the
impact of irregular heavy drinking occasions in those
who are on average light to moderate drinkers, however.
Injuries
Alcohol use has long been identiﬁed as a major contributor
to injuries of all kinds, with established causal links (for de-
tails see previous reviews [23,24]). Blood alcohol concen-
tration is the most important dimension to impair vision,
psychomotor skills/abilities and reaction-time; all these
processes and others in the central nervous system can
be affected negatively, starting at as low as 0.03% blood
alcohol concentration by volume [310]. In addition, as
already mentioned above, judgement about risk-taking
and other behavioural actions is impacted by alcohol use,
again dose-dependent. The dose–response relationship
between acute alcohol use, measured through the blood
alcohol concentration and injury, seem exponential for all
injury types, albeit varying slightly by type of injury
[311–313].
However, there is also interindividual heterogeneity,
based in part on usual drinking habits. For instance,
Krüger and colleagues found that for any given blood
alcohol concentration, the risk for trafﬁc injury would be
lower for a driver who is a regular heavy drinker than for
a light drinker [314]. In other words, average volume of
alcohol use also plays a role, even though this complexity
of an interaction between acute and typical alcohol use is
not modelled in current CRAs [315] or in other modelling
of alcohol-attributable injury harm [316].
The impact of alcohol use on suicide may be different
from other types of injury, as it seems to be determined
more by long-term drinking patterns, such as heavy drink-
ing or alcohol use disorders (e.g. [317,318], even though
there are also acute effects of alcohol use, e.g. on judge-
ment [319,320]. Thus, it should be considered to model
suicide in future CRAs differently from other types of injury,
with more emphasis on chronic patterns of drinking, in
particular heavy drinking.
Current modelling of alcohol-attributable injuries in
CRAs takes into account the number of drinking occasions
of different sizes and the relative risks associated with these
different exposures (for the most comprehensive analyses
on risk relations see [311]; for others see [312,313]; for
the exact methodologies see [321,322]). The last estima-
tion, as part of the larger study for the WHO European
Region estimating alcohol-attributable mortality in more
than 50 countries for 25 years, revealed [178] that
alcohol-attributable injury rates did not decrease in the
time-period in the same way as injuries in general [323].
The ﬁnal consideration about alcohol-attributable
injury is the estimation of harm to others than the drinker
from injuries, which is described below.
Overview on biological pathways and CRA modelling
strategies for each cause of death
Table 3 gives an overview of biological reasoning and CRA
modelling for all partially attributable disease and injury
categories. To explain further how to interpret this Table,
let us give one example: haemorrhagic and other
non-ischaemic stroke. As indicated, the current statistical
model is based on average volume of alcohol consumption
only [375]; see also the graphs in Supporting information,
Appendix S2). However, the biological pathways (see above
and Table 2) would clearly indicate an additional role for
irregular heavy drinking occasions which could not be
included to date into the model due to lack of data.
As can be seen, for several disease categories biological
pathways would suggest more complex statistical models,
which cannot be realized via the usual meta-analytical
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procedures because of lack of data from underlyingmedical
epidemiological studies.
Overview on different dimensions of alcohol use and
disease and injury outcomes
Figure 1 tries to summarize our knowledge about the
strength of the relationships between volume of alcohol
consumption, on one hand, and speciﬁc heavy drinking oc-
casions, on the other hand, and major disease categories.
On one end of the spectrum are cancers, which all show
a more or less linear relationship between alcohol use
and risk of cancer as expressed in logarithmized relative
risk compared to life-time abstention: the higher the (aver-
age) volume of alcohol use, the higher the risk for cancer.
The use of logarithmic scales for risk relations is customary
for the statistical techniques used, meaning that a linear
relationship in logarithmized relative risks actually trans-
lates into exponential risk relations in the real scales.
At the other end of the spectrum are ischaemic diseases
(i.e. ischaemic heart disease and ischaemic stroke), where
there is a curvilinear relationship between average volume
of alcohol use and risk, which ismodiﬁed by heavydrinking
occasions. Heavy drinking occasions seem primarily to
determine the adverse risk and subsequent harm. In socie-
ties where most of the alcohol is consumed in non-heavy
drinking occasions, we expect an overall beneﬁcial rela-
tionship of alcohol use on ischaemic diseases and an overall
very small net impact of alcohol use on cardiovascular dis-
ease andmortality; in societies wheremost of the alcohol is
consumed via heavy drinking occasions, the overall rela-
tionship should be detrimental for ischaemic disease, and
evenmore so for cardiovascular disease and death. This hy-
pothesis was also corroborated by the recent 25-year trend
analyses on alcohol-attributable mortality in 52 countries
of theWHO European Region [178]. While such a hypoth-
esis is based on individual-level studies, it could not always
be conﬁrmed in ecological analyses such as time–series
analyses (for conﬁrmation see [5,324]; for essentially no re-
lations in a number of countries in the EuropeanUnion, see
[325]; for a result contrary to the hypothesis, see [326]).
However, ecological analysis may be impacted by other
factors which cannot be controlled [327]. For the disease
categories in between, the ranking from top to bottom
may be interpreted as deviation from a straight line (linear
relationship) between alcohol use and relative risk of the
respective disease category: the higher the impact of heavy
drinking occasions, the more accelerated is the curve.
Figure 1 The impact of volume of alcohol use
and heavy drinking upon major attributable dis-
ease outcomes.
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Summary of changes since the last review
Table 4 gives an overview of changes for partially attribut-
able disease categories since the 2010 review [24]. Fewer
changes can be seen for injury, although there have been
new meta-analyses (see above) which are to be included
in the planned new Global Status Report. Alcohol epidemi-
ology is clearly a fast-moving ﬁeld, and our knowledge
about alcohol’s impact upon disease and mortality has in-
creased. Clearly, as there have been no major updates in
the ICD during the time from the last review, these catego-
ries have been stable.
Health harm to others
Like tobacco, alcohol has amarked impact upon the health
of others than the drinker [328–331]. Drinking of others as
an external cause is usually not measured in health system
classiﬁcations [332], so these impacts have to be estimated
otherwise. In terms of CRAs, minimally three categories
need estimation:
• The impact of alcohol use during pregnancy on the
health of the child: this can be captured mainly via
FASD and FAS, as described above, and new algorithms
for estimating incidence and prevalence of these condi-
tions based on mother’s drinking during pregnancy
have been developed [74]. Prevalence can then be
multiplied with disability weights to derive burden
(see above). Regarding fatal outcomes of FAS: while a
recent study has found a life expectancy of 34 years
[333], the overwhelming majority of these deaths are
coded as resulting from comorbidities [57], and are
not coded to FAS as a cause of death.
• Alcohol use of others can have marked impact on all
unintentional injuries. For instance, drinking by a pa-
rental care-giver increases the chances of uninten-
tional injury to a toddler [334], and parental alcohol
misuse is a powerful predictor of a child’s traumatic
brain injury [335]. Although others’ drinking can im-
pact upon a wide variety of unintentional injuries, it
has been studied most fully in the context of driving
and other trafﬁc participation under the inﬂuence of
alcohol (e.g. [329,336]). The burden in trafﬁc injuries
and fatalities, at least, can now be estimated more ac-
curately, as there are global statistics by sex of driver
and average number of passengers in each car [337].
• The impact of alcohol on aggression and violence to
others has been well established [23,338,339]. How-
ever, its quantiﬁcation becomes extremely compli-
cated, as drinking of the victim [311,340,341] and
drinking of the perpetrator seem to impact upon
the risk and severity of violent acts [340,342], the
latter possibly in a curvilinear fashion [340]. More-
over, the impact of alcohol use on violence is
mediated by other variables [342,343], including byTa
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culture [344]. While all these mediating and moder-
ating variables complicate estimation (for a ﬁrst try
within the framework of the CRAs see [345]), the
estimates found so far seem to indicate large effect
sizes: thus, English and colleagues estimated that ap-
proximately half the hospitalizations due to assault
were attributable to alcohol [31], and male homicide
deaths in the Soviet Union dropped by 40% when
per capita consumption dropped by 25% [346].
DISCUSSION
This systematic review has shown that many disease and
mortality outcomes are impacted causally by alcohol,
most often in an accelerated dose–response fashion. Since
the last review [24], many new reviews and meta-
analyses have appeared (see Table 4 and Supporting infor-
mation, Appendix S1 for a complete listing), but while
new alcohol-attributable disease categories have been
added, the general picture of alcohol use being a major
contributor to the burden of mortality and disease has
not changed.
Any systematic review is limited by the underlying liter-
ature. While the depth and quality of the literature varies
by disease and mortality category, it is unfortunately still
true that exposure measurement in many epidemiological
studies is restricted to one measure of average volume of
consumption, e.g. from a food frequency questionnaire or
from simple quantity–frequency measures (for an explana-
tion of these measures and their strengths see [347]). Even
though in recent years there have been more attempts to
quantify other dimensions such as irregular heavy drink-
ing occasions, these changes have come slowly, and for
many outcomes meta-analyses on patterns of drinking
are not possible. Moreover, many studies measure alcohol
use only once at baseline, and no changes of use over time
can be incorporated into the models. Finally, the compari-
son group still is a problem [174]: while using last-year ab-
stention may bias results by introducing sick-quitters
[348], life-time abstention may be the theoretically pre-
ferred measure but has been proven to be unreliable
[173], and in many high-income countries life-time
abstainers are special groups which also differ on other
outcome-relevant measures. In summary, very little has
changed since 2000, when these points had been already
listed as barriers for improving knowledge on alcohol use
and mortality outcomes [349]. Mendelian randomization
studies were added to our methodological arsenal
[224,259], but their assumptions are problematic if two
dimensions are to be analysed simultaneously with one
instrumental variable, as in the analyses on the impact of
alcohol use on ischaemic heart disease ([266]; see also
the discussion in the British Medical Journal [259]).Improv-
ing measurement of alcohol exposure (including but not
limited to measurement of chronic and irregular heavy
drinking), as described in the limitations above, should be
one of the research priorities. Other research priorities
(see also [1]) include:
• Improving incorporating time lags [186] into future
CRAs: this applies not only to effects of alcohol use, but
also to all risk factors, as CRAs need to be comparative.
• Improving our knowledge about risk relations: as indi-
cated above, for most countries with the exception of
Russia and surrounding countries [269], we assume
that risk relations taken from the most comprehensive
meta-analysis are applicable. Given the genetic and envi-
ronmental differences, we would expect some differences
in risk relations between alcohol use and disease/
mortality outcomes in different regions (see the example
of genetically based varying cancer risks described above,
which had marked implications for the population-level
burden of oesophagus cancer in Japan [175]; see also
some indications that alcohol use has different risk for
cardiovascular events in Asians versus non-Asians
[263,350]). The biggest difference in risk relations will
probably be found in injury outcomes, as these depend
more upon environment than disease [311,344].
However, for any regional differences in risk, it has
to be checked if these cannot be ascribed to differ-
ences in drinking patterns ﬁrst, before they are applied
to CRAs.
• Improvingour knowledge on health harm to others: cur-
rently, only a few studies exist on harm to others which
can be translated into a CRA framework, and this should
be a priority for future research. In particular, efforts to
improve the recording of alcohol’s involvement in
injuries in hospital or emergency service records (e.g.
[351,352]) should include attention to the involvement
of others’ drinking in the occurrence of the injury.
Wewould like to ﬁnish this reviewwith a reminder that
while the alcohol-attributable burden of disease and
mortality is large, it is only part of the harm of alcohol
use. Social harm outside of health harm is impacted by
similar dimensions of alcohol use (e.g. [90,353]), and
should be included in any considerations of the overall
impact of alcohol use in our societies.
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